open access
Whole abdominal radiotherapy in ovarian cancer
open access
Abstract
Objectives
The aim of the study was to evaluate the clinical outcome and toxicity after adjuvant whole abdominal radiotherapy (WART) in patients with ovarian cancer.
Material and methods
Ten patients with optimal cytoreduced ovarian cancer, with a mean age of 58 years (40–70) and stage Ic: 4, stage II: 2, stage III: 4, were treated with WART and adjuvant chemotherapy (9/10). The total radiation dose was 22.5[[ce:hsp sp="0.25"/]]Gy in the whole abdomen and 42–45[[ce:hsp sp="0.25"/]]Gy in the pelvis.
Results
The mean follow-up was 8 years. The 5-year actuarial disease-free survival (DFS) was 60%, and the overall survival (OS) was 70%. Four patients had disease recurrence. The sites of recurrence were the abdomen in 2 patients and distant metastases in the other 2 patients (liver and brain metastasis). Gastrointestinal toxicity was as follows: acute 3/10 grades I and II, and late toxicity: 2/10 grades I and II, and only 1 patient developed small bowel obstruction (SBO) that required surgery.
Conclusions
Whole abdominal radiotherapy after surgery and platinum-based chemotherapy achieves high locoregional disease control with an acceptable risk of acute toxicity.
Abstract
Objectives
The aim of the study was to evaluate the clinical outcome and toxicity after adjuvant whole abdominal radiotherapy (WART) in patients with ovarian cancer.
Material and methods
Ten patients with optimal cytoreduced ovarian cancer, with a mean age of 58 years (40–70) and stage Ic: 4, stage II: 2, stage III: 4, were treated with WART and adjuvant chemotherapy (9/10). The total radiation dose was 22.5[[ce:hsp sp="0.25"/]]Gy in the whole abdomen and 42–45[[ce:hsp sp="0.25"/]]Gy in the pelvis.
Results
The mean follow-up was 8 years. The 5-year actuarial disease-free survival (DFS) was 60%, and the overall survival (OS) was 70%. Four patients had disease recurrence. The sites of recurrence were the abdomen in 2 patients and distant metastases in the other 2 patients (liver and brain metastasis). Gastrointestinal toxicity was as follows: acute 3/10 grades I and II, and late toxicity: 2/10 grades I and II, and only 1 patient developed small bowel obstruction (SBO) that required surgery.
Conclusions
Whole abdominal radiotherapy after surgery and platinum-based chemotherapy achieves high locoregional disease control with an acceptable risk of acute toxicity.
Keywords
Ovarian cancer; Whole abdominal radiotherapy; Gastrointestinal toxicity
About this articleTitle
Whole abdominal radiotherapy in ovarian cancer
Journal
Reports of Practical Oncology and Radiotherapy
Issue
Pages
27-30
Published online
2010-03-01
DOI
10.1016/j.rpor.2010.02.004
Bibliographic record
Rep Pract Oncol Radiother 2010;15(2):27-30.
Keywords
Ovarian cancer
Whole abdominal radiotherapy
Gastrointestinal toxicity
Authors
Alberto Biete
Izaskun Valduvieco
Angels Rovirosa
Blanca Farrús
Francesc Casas
Carlos Conill